CD86 and acute myeloid leukemia: Preclinical studies have revealed that pharmacological LSD1 inhibition can promote the expression of cell surface markers, including CD11b and CD86, associated with a differentiated immuno-phenotype in 12 of 13 AML cell lines [4, 32].